1-6 of 6
David P. Schenkein, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

IDH1 Mutant Inhibitor Induces Cellular Differentiation and Offers a Combination Benefit With Ara-C In a Primary Human Idh1 Mutant AML Xenograft Model

Katharine Yen, Ph.D., Rene Lemieux, Ph.D., Janeta Popovici-Muller, Yue Chen, Ph.D., Hua Yang, Kim Straley, Sung Choe, Marion Dorsch, Samuel Agresta, MD, David P. Schenkein, MD, Scott Biller, Michael Su, Fang Wang
Journal: Blood
Blood (2013) 122 (21): 3946.
https://doi.org/10.1182/blood.V122.21.3946.3946
Published: 2013
Journal Articles

AG-221 Offers a Survival Advantage In a Primary Human IDH2 Mutant AML Xenograft Model

Katharine Yen, Ph.D., Fang Wang, Jeremy Travins, Yue Chen, Ph.D., Hua Yang, Kim Straley, Sung Choe, Marion Dorsch, David P. Schenkein, MD, Samuel Agresta, MD, Scott Biller, Michael Su
Journal: Blood
Blood (2013) 122 (21): 240.
https://doi.org/10.1182/blood.V122.21.240.240
Published: 2013
Journal Articles

Mutation Selective IDH Inhibitors Mediate Histone and DNA Methylation Changes

Katharine Yen, Fang Wang, Stefanie Schalm, Erica Hansen, Kimberly Straley, BS, Andrew Kernytsky, Sung Choe, Wei Liu, Janeta Popovici-Muller, Jeremy Travins, Hua Yang, Lee Silverman, Julie Losman Aurore, William G. Kaelin, Jr., MD, Stefan Gross, Lenny Dang, Frank Salituro, Jeffrey Saunders, Marion Dorsch, Samuel Agresta, MD, David P. Schenkein, MD, Michael Su, Scott Biller
Journal: Blood
Blood (2012) 120 (21): 3509.
https://doi.org/10.1182/blood.V120.21.3509.3509
Published: 2012
Journal Articles

2-Hydroxyglutarate in IDH mutant AML: Predicting Patient Responses, Minimal Residual Disease and Correlations with Methylcytosine and Hydroxymethylcytosine Levels

Daniel A Pollyea, MD, MS, Holbrook E Kohrt, MD, Bing Zhang, MD, MS, James L. Zehnder, MD, David P. Schenkein, MD, Valeria Fantin, PhD, Kimberly Straley, BS, Aparna Vasanthakumar, BSc, MSc, PhD, Omar Abdel-Wahab, MD, Ross L Levine, MD, Lucy Godley, MD, PhD, Bruno C. Medeiros, MD
Journal: Blood
Blood (2011) 118 (21): 2509.
https://doi.org/10.1182/blood.V118.21.2509.2509
Published: 2011
Journal Articles

A Phase 2 Study of Bortezomib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL).

Sven de Vos, MD, PhD, Donna Fernando, MAOM, David P. Schenkein, MD, Peter J. Rosen, MD
Journal: Blood
Blood (2005) 106 (11): 4746.
https://doi.org/10.1182/blood.V106.11.4746.4746
Published: 2005
Journal Articles

PAD Combination Therapy (PS-341/Bortezomib, Adriamycin and Dexamethasone) for Previously Untreated Patients with Multiple Myeloma.

James D. Cavenagh, MD, Rakesh Popat, MB BS, Nikki Curry, MB BS, Jim Stec, PhD, Treen C. Morris, FRCP, Mary Drake, MRCPath, Samir Agrawal, PhD, Patricia Smith, RGN, David P. Schenkein, MD, Dixie-Lee Esseltine, MD, Heather Oakervee, MRCP
Journal: Blood
Blood (2004) 104 (11): 1478.
https://doi.org/10.1182/blood.V104.11.1478.1478
Published: 2004